Valuation: Theriva Biologics, Inc.

Market Cap 10.33M 9.18M 8.57M 7.81M 14.73M 993M 14.86M 104M 40.17M 508M 38.79M 37.94M 1.63B P/E 2026 *
-0.87x
P/E 2027 * -0.98x
Enterprise Value 10.33M 9.18M 8.57M 7.81M 14.73M 993M 14.86M 104M 40.17M 508M 38.79M 37.94M 1.63B EV / Sales 2026 *
34.4x
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
-
Yield 2027 * -
09-30 Theriva? Biologics Announces Publication of the Results from the Virage Phase 2B Clinical Trial of Vcn-01 in Metastatic Pancreatic Cancer Published in Nature Medicine CI
08-11 Theriva Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-06 Theriva Biologics Doses First Patient in Virage2 Phase 2A Clinical Trial to Evaluate More Frequent Dosing of Vcn-01 in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI
07-07 Theriva Biologics Announces Regulatory Authorization to Proceed with Virage2 Phase 2A Clinical Trial to Evaluate More Frequent Dosing of Vcn-01 in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI
07-07 Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy MT
06-11 Theriva Biologics, Inc. Announces Clinical and Translational Results from VCN-01's Phase 1 Clinical Trial in Head & Neck Squamous Cell Carcinoma CI
05-05 Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-20 Top Premarket Gainers MT
04-17 Theriva Biologics announces upcoming presentation of additional data from the Virage phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer at AACR 2026 annual meeting RE
03-23 Theriva Biologics Announces Positive End-Of-Phase 2 Meeting With U.S. FDA Regarding The Design Of A Phase 3 Trial Of VCN-01 In Metastatic Pancreatic Ductal Adenocarcinoma CI
03-12 Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-11 Theriva Biologics, Inc. Auditor Raises 'Going Concern' Doubt CI
02-18 Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications RE
1 day+0.04%
1 week+2.04%
Current month+0.04%
1 month-11.03%
3 months-10.32%
6 months-2.09%
Current year+6.99%
1 week 0.21
Extreme 0.21
0.24
1 month 0.21
Extreme 0.21
0.25
Current year 0.16
Extreme 0.1628
0.49
1 year 0.16
Extreme 0.1628
0.86
3 years 0.16
Extreme 0.1628
17.11
5 years 0.16
Extreme 0.1628
114
10 years 0.16
Extreme 0.1628
16,187.5
Manager TitleAgeSince
Chief Executive Officer 64 2017-12-04
Chief Tech/Sci/R&D Officer - 2012-04-17
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 62 2012-05-13
Director/Board Member 63 2005-12-31
Director/Board Member 64 2018-12-05
Date Insider Type Main position Quantity % Market Cap. Importance
1/5/26 Free

Chief Executive Officer

475,000 1.4035%
1/5/26 Free

Chairman

75,000 0.2216%
1/5/26 Free

Director

75,000 0.2216%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+2.04%-45.84%-98.26% 10.33M
+4.16%+3.04%+49.37%+94.17% 74.16B
+1.18%-2.32%+21.36%+80.88% 57.39B
+1.64%-1.40%+3.37%+37.18% 47.64B
+0.36%+0.81%+342.39%+748.97% 44.29B
-0.96%-4.50%+24.96%+31.45% 42.5B
-0.20%-0.77%+4.13%+111.69% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+3.75%+31.90%+29.14% 28.53B
+0.05%-1.64%-8.14%-12.10% 24.34B
Average +0.76%-0.32%+43.28%+107.72% 39.05B
Weighted average by Cap. +1.17%-0.84%+57.46%+139.97%

Financials

2026 *2027 *
Net sales 300K 267K 249K 227K 428K 28.84M 432K 3.01M 1.17M 14.74M 1.13M 1.1M 47.32M -
Net income -11.47M -10.19M -9.51M -8.67M -16.35M -1.1B -16.5M -115M -44.59M -563M -43.05M -42.11M -1.81B -14.73M -13.08M -12.21M -11.13M -20.99M -1.42B -21.19M -148M -57.27M -724M -55.29M -54.09M -2.32B
Net Debt - -
Logo Theriva Biologics, Inc.
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Employees
16
Date Price Change Volume
26-10-02 US$0.2251 +0.04% 399,098
26-10-01 US$0.2250 0.00% 427,022
26-09-30 US$0.2250 +7.14% 856,012
26-09-29 US$0.2100 -3.00% 462,731
26-09-28 US$0.2165 -1.86% 759,345
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2251USD
Average target price
2.500USD
Spread / Average Target
+1,010.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TOVX Stock